Cipla Update by Epic Research

Cipla, a global pharmaceutical company, has launched Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of Fixed Combinations in Europe and help manage health costs for respiratory treatment.





Cipla is currently trading at Rs. 566.30, up by 36.60 points or 6.91% from its previous closing of Rs. 529.70 on the BSE.





For more information ✆ - 0731-6642300 or Visit http://ift.tt/1doLhaI

Posted in: Indian Market Tips